This page traces the causal chain from CHCHD10 gene mutations to mitochondrial dysfunction and motor neuron degeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). CHCHD10 encodes a mitochondrial intermembrane space protein critical for cristae junction maintenance and oxidative phosphorylation (OXPHOS) complex stability.
| Property | Value |
|---|---|
| Gene Symbol | CHCHD10 |
| Chromosome | 22q11.23 |
| NCBI Gene ID | 400916 |
| OMIM | 615903 |
| Protein | Mitochondrial coiled-coil-helix-coiled-coil-helix domain protein 10 (~14 kDa) |
| Subcellular Location | Mitochondrial intermembrane space, cristae junctions |
| Diseases | ALS, FTD, mitochondrial myopathy, cardiomyopathy, spinal muscular atrophy |
| Chain Element | Description | Evidence |
|---|---|---|
| Risk Gene | CHCHD10 — causative gene for ALS-FTD spectrum | Pathogenic variants: S59L, R15L, G66V, G58R, P34S[1] |
| Molecular Dysfunction | Mitochondrial cristae junction loss, OXPHOS complex instability | Mutations disrupt MICOS complex, leading to cristae disorganization[2] |
| Downstream Effects | TDP-43 mislocalization, ATP depletion, metabolic rewiring | CHCHD10 LOF causes cytoplasmic TDP-43 accumulation[3] |
| Clinical Phenotype | Motor neuron degeneration, behavioral FTD, myopathy | Broad phenotypic spectrum from pure ALS to mitochondrial myopathy |
CHCHD10 mutations cause both loss-of-function and toxic gain-of-function effects:
CHCHD10 localizes to mitochondrial cristae junctions where it forms a complex with CHCHD2. This complex stabilizes the MICOS (mitochondrial contact site and cristae organizing system), which is essential for:
Loss of CHCHD10 function leads to:
A key link between mitochondrial dysfunction and ALS pathology:
S59L triggers a distinct metabolic stress response:
The final common pathway:
| Approach | Target | Status |
|---|---|---|
| Mitochondrial protective agents | Stabilize cristae, boost OXPHOS | Preclinical |
| Anti-aggregation strategies | Inhibit amyloid fibril formation | Preclinical |
| Metabolic stress response modulators | Modulate ISR, enhance proteostasis | Preclinical |
| PDE4 inhibitors | Reduce CHCHD10 toxicity | FDA-approved drugs being repurposed[5] |
| Gene | Primary Mechanism | Key Feature |
|---|---|---|
| CHCHD10 | Mitochondrial cristae dysfunction | TDP-43 link |
| SOD1 | Protein misfolding/aggregation | First ALS gene |
| FUS | RNA processing dysfunction | Nuclear import defect |
| C9orf72 | RNA foci, dipeptide repeat toxicity | Most common genetic cause |
| TDP-43 | TDP-43 aggregation | Sporadic ALS hallmark |
| VCP | Autophagy impairment | Multisystem proteinopathy |
| TBK1 | Autophagy, neuroinflammation | Immune regulation |
CHCHD10 is unique among ALS-FTD genes in directly linking mitochondrial cristae dysfunction to TDP-43 pathology.
CHCHD10 mutations produce a remarkably broad spectrum:
CHCHD10 should be included in NGS panels for:
A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. 2014. ↩︎
CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis. 2016. ↩︎
Loss of function CHCHD10 mutations in cytoplasmic TDP-43 accumulation and synaptic integrity. 2017. ↩︎
Amyloid fibril structures link CHCHD10 and CHCHD2 to neurodegeneration. 2024. ↩︎
FDA-approved PDE4 inhibitors reduce CHCHD10 toxicity. 2024. ↩︎